9th Annual Biomarkers Congress

Proteomics: Pfizer

Total Score People Score Events Score
45 38 26
Date Event Presentation Speakers
April 28, 2014 Companion Diagnostics: From Biomarker Identification to Market Entry Case Study: Xalkori Companion Diagnostic Hakan Sakul
March 19, 2014 3rd Neurological Biomarkers Coalition Against Major Diseases (CAMD): Regulatory Science Accelerates Drug Development and Biomarkers for Neurodegenerative Diseases Diane Stephenson
September 19, 2011 The Role of Biomarkers in Clinical Trials A core microRNA signature of lung inflammation in rat and man Sterghios Moschos
January 31, 2011 Biomarkers Summit STREAM TWO | BIOMARKERS FOR INHALED ANTI-INFLAMMATORY THERAPIES – SAMPLING THE LUNG Iain Kilty
STREAM ONE | URINARY BIOMARKERS IN THE CLINICAL PROGNOSIS AND EARLY DETECTION OF ACUTE KIDNEY INJURY (AKI) Mark Fidock
STREAM TWO | DEVELOPING PROOF-OF-PHARMACOLOGY BIOMARKERS Mark Fidock
Chairman's opening remarks Mark Fidock
January 13, 2011 Inaugural Protein Computational Tools Structure-Based Design of Therapeutic Antibodies for Improved Developability Sandeep Kumar
May 19, 2010 Engineering Antibodies Use of Disposable Label-Free Real-Time Biosensors in Epitope Binning Monoclonal Antibodies Yasmina Abdiche
May 19, 2010 Protein Aggregation in Biopharmaceutical Products Biophysical Techniques to Explore Protein Aggregation or Aggregation Propensity Min Huang
May 4, 2010 Biomarker World Congress 2010 Pre-clinical Translational Biomarkers: Enabling Early Predictions Using PK/PD Mark Fidock
April 6, 2010 IBCs 5th Annual China 2010 Pharmaceutical R&D Summit China's Pharmaceutical Industry from the Insiders' Eyes Steve Yang
Chairperson's Opening Remarks Steve Yang
4 Simultaneous Global Development - What Does It Mean for China? Bradley Merchant
An MNC's Perspective on the Overall Capabilities of China's Biosimilars/FOB Development - A Comparison with US/EU Yining Zhao
Martin Mackay, Ph.D. Right Targets. Right Patients. Right Now. Martin Mackay
October 6, 2009 Third Annual Improving Protein Expression Through Innovation Saving Time and Costs for Antibody Expression in Mammalian Cells Gerald Casperson
Therapeutic Antibody Production in Mammalian Cells at Lab Scale: Comparison, Adaptation and Implementation of Strategies for Time and Cost Savings Gerald Casperson
August 24, 2009 Fifth Annual Optimizing Cell Culture Technologies Using Systematic Metabolite Analysis to Guide Cell Culture Process Optimization Zhaohui Geng
A Scalable Human Adipocyte Model for the Study of Insulin Resistance Deb Nathan
August 5, 2009 Targets in Context - Linking Targets to Diseases Agenda Human Genetics and Disease Relevant Targets: Linking Clinical Outcomes to Targets Albert B. Seymour
RNAi in Practice Ð Assays and Screening in Mammalian Cells Steven Haney
Tissue Engineered Tumor Niches as Drug Testing Platforms Eric YH Park
January 26, 2009 Pre-Conference Short Course* Jean W Lee
January 26, 2009 Biomarker Assay Development Assessment of Free-and Total- Drug Concentration in the Development of Biotherapeutic Agents - Analytical and Biological Considerations Scott Fountain
Quantification of “Total” and/or “Free” Target Protein Biomarker: Approaches and Applications Jean W Lee
Low Abundance Protein Biomarker Quantitation Using Immunoaffinity Enrichment And Nanoflow LC-MS/MS Hendrik Neubert
Validating Cell-Based Biomarker Assays Iman Jilani
January 26, 2009 Translational Cancer Medicine Pre-Conference Short Course* : Fit-for-Purpose Biomarker Assay Development and Validation Jean W Lee
SUNITINIB : Guidance Toward Sunitinib Clinical Development Strategy through Translational Research Approaches James Christensen
December 4, 2008 BIT Life Sciences 2nd Annual World Congress of Gene-2008 (WCG 2008) Title: TBD :Track 2-3 Yuan-Hua Ding
September 29, 2008 Metabolic Biomarkers Pre-Conference Tutorial* (*Separate Registration Required) Jean W Lee
September 17, 2008 BACULOVIRUS TECHNOLOGY Parallel Protein Production in the Baculovirus Expression Vector System for Structure-Based Drug Design Ciaran Cronin
July 19, 2008 22nd Annual Symposium of The Protein Society Concurrent Afternoon Symposia 4: Signal Transduction Networks as Molecular Machines: Implications for Drug Discovery Preston Hensley
January 6, 2008 Structural Genomics and its Applications to Chemistry, Biology and Medicine Workshop 1: Applications of Structural Genomics for Structural Biology David C. Wood
November 5, 2007 Second Annual Biomarkers Europe Nov (05-06) BIOMARKERS FOR EARLY CLINICAL TRIALS (08:00-12:15) Mark Fidock, Karthik Venkatakrishnan
BIOMARKERS FOR EARLY CLINICAL TRIALS: Biomarker-Based Quantitative Risk Assessment for CYP3A Induction DDI in Early Clinical Development (11:30-12:00) Karthik Venkatakrishnan
BIOMARKERS FOR EARLY CLINICAL TRIALS: Lost in Translation (10:30-11:00) Mark Fidock
BIOMARKER QUALIFICATION AND VALIDATION: A Cost Effectiveness Approach to the Qualification and Acceptance of Biomarkers (16:45-17:15) David E. Slavin
BIOMARKER QUALIFICATION AND VALIDATION (15:45-17:45) David E. Slavin
September 30, 2007 BioProcess International Conference & Exhibition Pre-Conference Workshops A & B (13:30 - 17:00) Gerald F. Casperson
Pre-Conference Workshop B (13:00 - 17:00) Gerald F. Casperson
Pre-Conference Workshop B: Protein Production Via Large Scale Transient Transfection of Mammalian Cells Gerald F. Casperson
Production & Economics of Biopharmaceuticals, Strategies for Flexible Facility Design and Capacity Optimization (07:00 - 11:30) James Bouressa,
Strategies for Flexible Facility Design and Capacity Optimization : Optimizing the Use of a Multi-Product Biologics Clinical Manufacturing Facility James Bouressa,
Scaling Up from Bench through Commercialization , Best Practices for Strategic Scale Up Decisions (07:00 - 12:15) Ellen L. McCormick
Best Practices for Strategic Scale Up Decisions: CP-675,206: Manufacturing Strategy toward BLA/MAA Ellen L. McCormick
Scaling Up from Bench through Commercialization ; Regulatory and Quality Considerations (13:45 - 17:45) Thomas P. Garcia
Regulatory and Quality Considerations : Update on Experience with FDA Pilot Program Thomas P. Garcia
Market Forces and Technology Developments Affecting Economics of Biopharmaceuticals : Using Process Simulation to Prioritize Development Activities Joseph K. McLaughlin
Production & Economics of Biopharmaceuticals ; Market Forces and Technology Developments Affecting Economics of Biopharmaceuticals (08:00 - 11:30) Joseph K. McLaughlin
September 27, 2007 Protein Expression Europe (Sep 27-28) Parallel Approaches Continued (09:00-11:40) Ciaran Cronin
Parallel Approaches Continued: A Model for Parallel Protein Production (10:40-11:10) Ciaran Cronin
Drug Discovery Applications (13:00-15:15) Stephen Irving
Drug Discovery Applications: Overcoming Challenges in Supplying Proteins for Structural Biology (14:15-14:45) Stephen Irving
September 17, 2007 Optimizing Cell Culture Development (Sep17-18) OPTIMIZING CELL LINES (08:30-10:50) S. Edward Lee
OPTIMIZING CELL LINES: An Alternative Method for Cell Line Adaptation (09:05-09:35) S. Edward Lee
September 17, 2007 Biomarker Discovery Summit: Bridging the Silos in Biomarker Discovery & Validation (Sep17-19) Third Annual Toxicity Biomarkers; TOXICITY BIOMARKER DISCOVERY (08:30-11:00) Frances Clemo
Third Annual Toxicity Biomarkers; TOXICITY BIOMARKER DISCOVERY: Preclinical Biomarkers of Hepatotoxicity: What’s new? (09:35-10:05) Frances Clemo
Pre-Conference Workshops; Biomarker Assay Development and Validation: Part I Tutorial FIT-FOR-PURPOSE BIOMARKER ASSAY DEVELOPMENT AND VALIDATION (08:00-12:00) Jean W Lee
July 7, 2007 Protein Kinases and Protein Phosphorylation Distinct and Overlapping actions of KSR1 and KSR2 In Vivo and In Vitro Marilyn Lewis
4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.